Latigo Biotherapeutics (LTGO) news
Recent news
Latigo Biopharma indicated to open at $22, IPO price $18
Latigo Biopharma’s shares opened at $22 on the Nasdaq on August 7, 2026, surpassing the initial offering price of $18 per share. The biotechnology firm raised $345.6 million through the sale of 19.2 million shares, marking a strong market reception for its initial public offering. The company’s…
AInvest Wire · Aug 7, 2026Latigo said to allocate zero shares to 70% of IPO orders
Latigo Bio, a biotechnology company preparing for an initial public offering (IPO), has reportedly allocated zero shares to 70% of IPO orders, according to recent filings and industry reports. This allocation strategy has raised questions among investors about the company’s approach to distributing…
AInvest Wire · Aug 7, 2026Latigo Biopharma indicated to open at $20, IPO price $18
Latigo Biopharma, a biotechnology company focused on developing non-opioid pain treatments, has indicated an initial public offering (IPO) price of $18 per share, with the stock expected to open trading at $20. The company, which has raised approximately $322 million since its founding in 2018,…
AInvest Wire · Aug 7, 2026Latigo Biopharma announces pricing of upsized $345.6 million initial public offering
AInvest Wire · Aug 7, 2026Latigo Biopharma said to guide IPO price at top of range
AInvest Wire · Aug 6, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.